Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Journal of Hepatology|September 14, 2016
Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patientsStanislas Pol, Marc Bourliere, Sandy Lucier, et al.
Hepatology (Baltimore, Md.)|June 28, 2016
Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir)Nathalie Ganne-Carrié, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|February 14, 2015
Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort)Jean-Claude Trinchet, Valérie Bourcier, Cendrine Chaffaut, et al.
Gastroenterology|July 22, 2018
Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance ProgramsPierre Nahon, Richard Layese, Valérie Bourcier, et al.
Gastroenterology|May 6, 2018
Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-Time Adjusted Survival of Patients With Compensated Viral Cirrhosis: A Multi-Center Cohort StudyCharlotte E Costentin, Richard Layese, Valérie Bourcier, et al.
Hepatology (Baltimore, Md.)|April 18, 2018
Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradicationManon Allaire, Pierre Nahon, Richard Layese, et al.
Gastroenterology|February 16, 2019
Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral TherapyDominique Thabut, Christophe Bureau, Richard Layese, et al.
Gut|October 30, 2015
Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort)Pierre Nahon, Mathilde Lescat, Richard Layese, et al.
Gastroenterology|September 20, 2016
Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver ComplicationsPierre Nahon, Valérie Bourcier, Richard Layese, et al.
American Heart Journal|April 15, 2018
Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patientsPatrice Cacoub, Pierre Nahon, Richard Layese, et al.
Pageof 3